-
Primary immunogenicity objective:
To compare the hemagglutination inhibition geometric mean titers to influenza A antigens in adult SOT recipients after receiving either one dose of high dose quadrivalent influenza vaccine (HD-QIV), two doses of standard dose QIV, or two doses of HD-QIV over one influenza season.
Primary safety objectives:
To compare the frequency and severity of solicited local injection site adverse events.
To compare the frequency and severity of solicited systemic adverse events.
Funded by the NIH: https://reporter.nih.gov/project-details/10875512
For more information: https://clinicaltrials.gov/study/NCT04613206
-
Primary immunogenicity objective:
To compare the hemagglutination inhibition geometric mean titers to influenza A antigens in lung transplant recipients after receiving either two doses high dose (HD)- Trivalent inactivated influenza vaccine (TIV) or two doses of standard dose (SD)-TIV (2024-2025).
Primary safety objectives:
To compare the frequency and severity of local solicited adverse events in lung transplant recipients after receiving either two doses of HD-TIV or two doses of SD-TIV (2024-2025).
To compare the frequency and severity of systemic solicited adverse events in lung transplant recipients after receiving two doses of HD-TIV or two doses of SD-TIV (2024-2025).
Funded by the NIH: https://reporter.nih.gov/project-details/10770519
For more information: https://www.clinicaltrials.gov/study/NCT05215327
-
Primary immunogenicity objectives:
To compare additional measures of hemagglutination inhibition assay (HAI) immunogenicity between intervention groups
To compare vaccine effects on immunogenicity following 1st and 2nd doses between HD-QIV and SD-QIV recipients.
To compare durability of influenza vaccine immunogenicity at the end season (at least 6 months following 1st study vaccine) between study intervention groups.
Primary safety objectives:
To compare the frequency and severity of serious and/or unexpected systemic adverse events in pediatric SOT recipients between the two study intervention groups.
To compare the frequency and severity of each of de novo post-vaccine DSA development and acute rejection events in pediatric SOT recipients after receiving either two doses of SD-QIV or two doses of HD-QIV over one influenza season
Funded by the NIH: https://reporter.nih.gov/project-details/10863881
For more information: https://clinicaltrials.gov/study/NCT05947071
-
The New Vaccine Surveillance Network (NVSN) is CDC’s multi-pathogen enhanced surveillance network to assess pediatric viral respiratory and gastrointestinal infections and vaccine impact in children.
Acute respiratory illness (ARI) surveillance includes RSV, SARS-CoV-2, influenza virus, adenovirus, parainfluenza viruses 1-4, seasonal human coronaviruses, human metapneumovirus, and rhinoviruses/enteroviruses (RV/EV), including enterovirus-D68. Surveillance was expanded to include multisystem inflammatory syndrome in children (MIS-C) in 2022.
Acute gastroenteritis (AGE) surveillance includes rotavirus and norovirus.
For more information: https://www.cdc.gov/nvsn/php/about/index.html
-
A prospective cohort study to define infectious burden, the seroprevalence of vaccine preventable pathogens and immune recovery in the first year following completion of therapy in patients with acute lymphoblastic leukemia (ALL).
Primary objectives:
To determine the overall infection incidence rate within the first year following completion of therapy for ALL.
Describe the seroprevalence for pneumococcus, varicella, and measles at approximately 3-, 6-, and 12-months following completion of therapy in patients with ALL and describe B and T lymphocyte subset recovery, specifically CD4+ T follicular helper cells, using peripheral blood mononuclear cells (PMBCs) at about 3-, 6-, and 12-months following completion of ALL therapy.
